avelumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 other
pharma · Systemic Lupus Erythematosus · Lupus Erythematosus, Systemic
Serana Europe
Serono Europe Limited
Serana Europe drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Pessin, DE HQ
2014 Founded
20 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Pessin, DE
- Founded
- 2014
- Employees
- 20
- Programs
- 8
- Drugs
- 8
- Patents
- 0
Serana Europe pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Serana Europe drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Serana Europe in public FDA and regional records.
-
Development asset linked to Serana Europe in public FDA and regional records.
-
Development asset linked to Serana Europe in public FDA and regional records.
-
Development asset linked to Serana Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
Development asset linked to Serana Europe in public FDA and regional records.
-
tepotinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Serana Europe's portfolio. Molecular target: Hepatocyte growth factor receptor.
- Target
- Hepatocyte growth factor receptor
- Mechanism
- Hepatocyte growth factor receptor inhibitor